The pharmaceutical trademark regulatory conflict within the Dominican Republic’s legal framework reveals a persistent and significant tension between the industrial property system and the public health regime in the pharmaceutical sector. The lack of alignment between these systems not only jeopardizes the legitimate rights of pharmaceutical laboratories but also creates inconsistencies that may ultimately affect the timely availability of medicines, fair competition, and even patient safety itself.
This conflict arises from a simple yet crucial premise: while trademarks aim to distinguish and position products in the market under principles of exclusivity and reputation, health regulators are tasked with safeguarding patient safety by preventing confusion in the private denominations of medicines. However, this duality of interests has led to scenarios in which a mark approved by the industrial property office is later rejected by the health authority for purposes of marketing authorization, often based on divergent or unpredictable criteria, as though the two authorities belonged to separate jurisdictions.
Although national legislation prohibits the registration of generic, misleading, or confusing denominations as trademarks, and even though the industrial property office applies particularly strict criteria for pharmaceutical classification, once a trademark becomes a prerequisite for a marketing authorization request, the health authority frequently invokes its own regulatory autonomy, which often lacks clear technical parameters, to reject marks already granted after lengthy registration proceedings. When such restrictions are applied without sufficient technical rigor or transparency, they can unnecessarily hinder market access, especially for innovative or imported products.
This tension is not unique to the Dominican Republic. In Mexico, for example, trademark registration is not a prerequisite for marketing authorization before COFEPRIS, creating uncertainty as to which procedure should be initiated first, since an unfavorable decision in either process may frustrate a product’s entire commercial strategy. In Brazil, in 2005, an unprecedented situation arose when the health authority (ANVISA) ordered the modification of long-established registered trademarks on the grounds that they were misleading or overly similar to other denominations, despite their recognition by the industrial property system. In the United States, even with existing coordination mechanisms between the FDA and the USPTO, cases of tension have been reported that have reignited this regulatory debate. Similar issues have emerged in Venezuela, Chile, Colombia, and other Latin American countries. Despite institutional differences, a common pattern is evident: a generalized lack of integration between intellectual property and health regulation, with consequences that fall squarely on rights holders and, ultimately, on patient access to safe and reliable medicines.
A reasonable solution does not require sacrificing public health objectives but rather establishing effective coordination mechanisms between both authorities. The development of joint technical guidelines, clearer delineation of each institution’s roles and powers, the creation of inter-agency committees where appropriate, and the adoption of predictable, technically grounded criteria are among the measures that could mitigate this friction. The ultimate goal should be a coherent and harmonized regulatory environment—one that upholds intellectual property rights without compromising patient safety and enables pharmaceutical companies to innovate, compete, and contribute solutions without facing disproportionate regulatory burdens or contradictory legal requirements.
Author:
Partner
Originally published in Legal Industry Reviews – Dominican Republic edition.
